EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial

Emmanuel Kobia-Acquah iD, Gareth Lingham iD, Daniel Ian Flitcroft, James Loughman iD

Acta Ophthalmologica · 2025

DOI: 10.1111/aos.17429 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Emmanuel Kobia-Acquah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Atropine, Choroid, Myopia, Refraction, Ocular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate 2‐year changes in macular choroidal thickness (ChT) in children receiving 0.01% atropine eyedrops and its relationship with spherical equivalent refraction (SER) progression and axial length (AL) elongation.

Methods

A total of 250 myopic children aged 6–16 years (167%–0.01% atropine, 83‐placebo) were enrolled in the MOSAIC ( ISRCTN36732601 ) clinical trial. Participants with complete 2‐year ChT (Topcon Triton Swept‐Source OCT), SER, and AL data were included in this study. Changes in macular ChT at 2 years and associations with changes in SER and AL elongation were analysed using linear mixed models.

Results

A total of 187 children (126%–0.01% atropine, 61‐placebo) were included in the analysis. Choroidal thickness over 2 years was stable in the 0.01% atropine compared with placebo group, which exhibited consistent thinning in subfoveal (mean ± SE: 0.49 ± 2.22 μm vs. −9.46 ± 2.69 μm; p = 0.034), parafoveal (1.40 ± 1.73 μm vs. −8.11 ± 2.08 μm; p = 0.002), and perifoveal (0.80 ± 1.25 vs. −6.17 ± 1.69; p = 0.002) macular subfields. Choroidal thickening was observed in participants with slower axial eye growth and myopia progression, regardless of their treatment group. Mediation analysis indicated that atropine 0.01% had a significant effect on ChT, with 68.3% of the effect being direct and 31.7% mediated through axial length changes. For SER, the direct effect on ChT was 80%, with the remaining 20% mediated by SER changes.

Conclusions

Myopic participants treated with 0.01% atropine exhibited stable ChT over 2 years, whereas the placebo group showed consistent thinning. The effect of atropine 0.01% on ChT was only partially explained by axial length and SER changes, indicating a direct effect of atropine treatment on the choroid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtropineChoroidMyopiaRefraction, OcularTomography, Optical CoherenceMacula LuteaHumansChildFemaleMaleOphthalmic SolutionsAdolescentMydriaticsFollow-Up StudiesDouble-Blind MethodAxial Length, EyeTime FactorsDisease ProgressionVisual AcuityDose-Response Relationship, Drug

Stichwörter der Autor:innen

atropinechildrenchoroidal thicknessmyopiarandomised controlled trial

Substanzen

AtropineOphthalmic SolutionsMydriatics

Autor:innen und Institutionen

  • Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.
  • Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Australia.
  • Department of Ophthalmology, Children's Health Ireland at Temple Street Hospital, Dublin, Ireland.

ORCID-Profile: Emmanuel Kobia-Acquah, Gareth Lingham, James Loughman

Zitieren

APA

Kobia-Acquah, E., Lingham, G., Flitcroft, D. I., & Loughman, J. (2025). Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial. Acta Ophthalmologica. https://doi.org/10.1111/aos.17429

Vancouver

Kobia-Acquah E, Lingham G, Flitcroft DI, Loughman J. Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial. Acta Ophthalmologica. 2025. doi:10.1111/aos.17429

BibTeX
@article{KobiaAcquah2025,
  author = {Kobia-Acquah, Emmanuel and Lingham, Gareth and Flitcroft, Daniel Ian and Loughman, James},
  title = {Two‐year changes of macular choroidal thickness in response to 0.01% atropine eye drops: Results from the myopia outcome study of atropine in children ( MOSAIC ) clinical trial},
  journal = {Acta Ophthalmologica},
  year = {2025},
  doi = {10.1111/aos.17429}
}
Kostenlos starten →